PLIVA 789 Pill - white oval, 20mm
Pill with imprint PLIVA 789 is White, Oval and has been identified as Azithromycin Monohydrate 600 mg. It is supplied by Pliva Inc.
Azithromycin is used in the treatment of Bacterial Infection; Bacterial Endocarditis Prevention; Babesiosis; Bartonellosis; Bronchitis and belongs to the drug class macrolides. There is no proven risk in humans during pregnancy. Azithromycin 600 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for PLIVA 789
Azithromycin Monohydrate
- Imprint
- PLIVA 789
- Strength
- 600 mg
- Color
- White
- Size
- 20.00 mm
- Shape
- Oval
- Availability
- Prescription only
- Drug Class
- Macrolides
- Pregnancy Category
- B - No proven risk in humans
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Pliva Inc.
- National Drug Code (NDC)
- 50111-0789
- Inactive Ingredients
-
croscarmellose sodium,
calcium phosphate dibasic anhydrous,
hypromellose 2910 (15 mPa.s),
lactose monohydrate,
polyethylene glycol 4000,
magnesium stearate,
microcrystalline cellulose,
corn starch,
trisodium citrate dihydrate,
sodium lauryl sulfate,
titanium dioxide
Note: Inactive ingredients may vary.
More about azithromycin
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1,296)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: macrolides
- Breastfeeding
- En español
Patient resources
- Azithromycin drug information
- Azithromycin (Intravenous) (Advanced Reading)
- Azithromycin Tablets
- Azithromycin Extended-Release Oral Suspension
- Azithromycin Injection
Other brands
Zithromax, Azithromycin Dose Pack, Zmax
Professional resources
- Azithromycin monograph
- Azithromycin Dihydrate (FDA)
- Azithromycin Injection (FDA)
- Azithromycin Oral Suspension (FDA)
- Azithromycin Tablets (FDA)
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
